Multiple Microvascular Alterations in Pancreatic Islets and Neuroendocrine Tumors of a Men1 Mouse Model

被引:25
|
作者
Chu, Xia [1 ]
Gao, Xiang [2 ]
Jansson, Leif [2 ]
Quach, My [2 ]
Skogseid, Britt [1 ]
Barbu, Andreea [1 ]
机构
[1] Uppsala Univ, Dept Med Sci, S-75185 Uppsala, Sweden
[2] Uppsala Univ, Dept Cell Biol, S-75185 Uppsala, Sweden
来源
AMERICAN JOURNAL OF PATHOLOGY | 2013年 / 182卷 / 06期
基金
瑞典研究理事会;
关键词
FIBROBLAST-GROWTH-FACTOR; ENDOCRINE NEOPLASIA TYPE-1; BLOOD-FLOW; NITRIC-OXIDE; IN-VIVO; MICROVESSEL DENSITY; ENDOTHELIAL-CELLS; FACTOR EXPRESSION; PDGF-B; ANGIOGENESIS;
D O I
10.1016/j.ajpath.2013.02.023
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Vascular therapeutic targeting requires thorough evaluation of the mechanisms activated in the specific context of each particular tumor type. We highlight structural, molecular, and functional microvascular aberrations contributing to development and maintenance of pancreatic neuroendocrine tumors (NETs), with special reference to multiple endocrine neoplasia 1 (MEN1) syndrome, using a Men1 mouse model. Tissue samples were analyzed by immunofluorescence to detect vessel density and pericyte distribution within the endocrine pancreas; expression of angiogenic factors was assessed by immunohistochemistry and quantitative real-time PCR in isolated islets and adenomas cultured under normoxic or hypoxic conditions. The increased vascular density of pancreatic NETs developed in Men1 mice was paralleled by an early and extensive redistribution of pericytes within endocrine tissue. These morphological alterations are supported by, and in some cases preceded by, fine-tuned variations in expression of several angiogenic regulators and are further potentiated by hypoxia. By combining two novel ex vivo and in vivo single-islet and tumor perfusion techniques, we demonstrated that both vascular reactivity and blood perfusion of tumor arterioles are significantly altered in response to glucose and L-nitro-arginine methyl ester. Our findings unravel multiple potential molecular and physiological targets differentially activated in the endocrine pancreas of Men1 mice and highlight the need for in-depth functional studies to fully understand the contribution of each component to development of pancreatic NETs in MEN1 syndrome.
引用
收藏
页码:2355 / 2367
页数:13
相关论文
共 50 条
  • [1] A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control
    Lines, K. E.
    Nunes, R. P. Vas
    Frost, M.
    Yates, C. J.
    Stevenson, M.
    Thakker, R. V.
    ENDOCRINE CONNECTIONS, 2017, 6 (04): : 232 - 242
  • [2] A mouse model of MEN1 develops multiple endocrine tumors.
    Crabtree, JS
    Scacheri, PC
    Ward, JM
    Garrett-Beal, L
    Emmert-Buck, MR
    Edgemon, KA
    Chandrasekharappa, SC
    Marx, SJ
    Spiegel, AM
    Collins, FS
    AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (01) : 292 - 293
  • [3] MEN1 associated pancreatic endocrine tumors can arise in islets
    Perren, A.
    Anlauf, M.
    Henopp, T.
    Rudolph, T.
    Schmitt, A.
    Raffel, A.
    Gimm, O.
    Weihe, E.
    Knoefel, W. T.
    Dralle, H.
    Heitz, P. U.
    Komminoth, P.
    Kloeppel, G.
    PATHOLOGY RESEARCH AND PRACTICE, 2007, 203 (05) : 384 - 384
  • [4] Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1)
    Caroline L. Lopez
    Barbara Joos
    Detlef K. Bartsch
    Jerena Manoharan
    Max Albers
    Emily P. Slater
    Carmen Bollmann
    Sylvia Roth
    Aninja Bayer
    Volker Fendrich
    World Journal of Surgery, 2019, 43 : 831 - 838
  • [5] Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1)
    Lopez, Caroline L.
    Joos, Barbara
    Bartsch, Detlef K.
    Manoharan, Jerena
    Albers, Max
    Slater, Emily P.
    Bollmann, Carmen
    Roth, Sylvia
    Bayer, Aninja
    Fendrich, Volker
    WORLD JOURNAL OF SURGERY, 2019, 43 (03) : 831 - 838
  • [6] Multiple neuroendocrine tumors in the stomach, duodenum and pancreas of a MEN1 patient
    Wang, Sihui
    Zhang, Wenjia
    Xu, Mengyue
    Xia, Min
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (06) : 339 - 341
  • [7] Active surveillance as a treatment option for pancreatic neuroendocrine tumors in the context of MEN1
    Yiannakopoulou, E.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 218 - 218
  • [8] Pancreatic Neuroendocrine Tumors in MEN1 Disease: A Monocentric Longitudinal and Prognostic Study
    Chiloiro, S.
    Bianchi, A.
    Lanza, F.
    Schinzari, G.
    Bima, C.
    Giampietro, A.
    Milardi, D.
    Grande, G.
    Piacentini, S.
    Tartaglione, L.
    Brizi, M. G.
    Rufini, V
    Rindi, G.
    Pontecorvi, A.
    De Marinis, L.
    NEUROENDOCRINOLOGY, 2017, 105 : 125 - 125
  • [9] Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model
    Quinn, Thomas J.
    Yuan, Ziqiang
    Adem, Asha
    Geha, Rula
    Vrikshajanani, Chakravarthy
    Koba, Wade
    Fine, Eugene
    Hughes, David T.
    Schmid, Herbert A.
    Libutti, Steven K.
    SURGERY, 2012, 152 (06) : 1068 - 1076
  • [10] A NEW PATTERN OF NEUROENDOCRINE TUMORS IN MEN1
    SCHEIMBERG, IB
    BISHOP, AE
    COLFOUR, AM
    WILLIAMSON, RCN
    POLAK, JM
    JOURNAL OF PATHOLOGY, 1991, 163 (02): : A165 - A165